Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AC Immune SA - Common Stock (NQ:ACIU)

3.250 +0.440 (+15.66%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 589,347
Open 2.810
Bid (Size) 3.100 (1)
Ask (Size) 3.340 (2)
Prev. Close 2.810
Today's Range 2.750 - 3.300
52wk Range 1.430 - 3.990
Shares Outstanding 99,197,829
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine
From AC Immune SA
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga

Performance

YTD
+14.0%
+14.0%
1 Month
+19.0%
+19.0%
3 Month
+33.7%
+33.7%
6 Month
+98.2%
+98.2%
1 Year
+8.3%
+8.3%

More News

Read More
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine
From AC Immune SA
Via GlobeNewswire
AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway
From AC Immune SA
Via GlobeNewswire
AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
From AC Immune SA
Via GlobeNewswire
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025
From AC Immune SA
Via GlobeNewswire
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
AC Immune to Participate in Upcoming Investor Conferences
From AC Immune SA
Via GlobeNewswire
Eliminating Some Screened Stocks
Via Talk Markets
Topics Stocks / Equities
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome
From AC Immune SA
Via GlobeNewswire
S&P 500 Moves Lower; US Crude Oil Inventories Increase
Via Benzinga
Topics Stocks
AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients
Via Benzinga
Hillenbrand Posts Better-Than-Expected Earnings, Joins Beazer Homes, Tapestry, Walt Disney And Other Big Stocks Moving Higher On Thursday
Via Benzinga
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
From AC Immune SA
Via GlobeNewswire
AC Immune to Present at the Jefferies 2024 London Healthcare Conference
From AC Immune SA
Via GlobeNewswire
AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
Why Granite Point Mortgage Trust Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease
From AC Immune SA
Via GlobeNewswire
AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions
From AC Immune SA
Via GlobeNewswire
AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024
From AC Immune SA
Via GlobeNewswire
AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease
From AC Immune SA
Via GlobeNewswire

Frequently Asked Questions

Is AC Immune SA - Common Stock publicly traded?
Yes, AC Immune SA - Common Stock is publicly traded.
What exchange does AC Immune SA - Common Stock trade on?
AC Immune SA - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for AC Immune SA - Common Stock?
The ticker symbol for AC Immune SA - Common Stock is ACIU on the Nasdaq Stock Market
What is the current price of AC Immune SA - Common Stock?
The current price of AC Immune SA - Common Stock is 3.250
When was AC Immune SA - Common Stock last traded?
The last trade of AC Immune SA - Common Stock was at 10/24/25 04:00 PM ET
What is the market capitalization of AC Immune SA - Common Stock?
The market capitalization of AC Immune SA - Common Stock is 322.39M
How many shares of AC Immune SA - Common Stock are outstanding?
AC Immune SA - Common Stock has 322M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.